NASDAQ:CELG - Celgene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$86.91 -0.39 (-0.45 %)
(As of 01/17/2019 12:00 PM ET)
Previous Close$87.30
Today's Range$86.68 - $87.27
52-Week Range$58.59 - $106.67
Volume2.77 million shs
Average Volume14.06 million shs
Market Capitalization$61.69 billion
P/E Ratio12.71
Dividend YieldN/A
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CELG


Current Ratio2.13
Quick Ratio1.99


Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.67
Cash Flow$7.5052 per share
Price / Cash Flow11.58
Book Value$8.79 per share
Price / Book9.89


Net Income$2.94 billion
Net Margins19.64%
Return on Assets16.75%


Market Cap$61.69 billion

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene declared that its board has authorized a share repurchase program on Thursday, May 24th 2018, which permits the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 5.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) announced its quarterly earnings data on Thursday, October, 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.02 by $0.27. The biopharmaceutical company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY19 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.32. The company issued revenue guidance of $17-17.2 billion, compared to the consensus revenue estimate of $16.93 billion.Celgene also updated its FY 2018 guidance to $8.75-8.80 EPS.

What price target have analysts set for CELG?

25 Wall Street analysts have issued 12-month price targets for Celgene's stock. Their predictions range from $77.00 to $150.00. On average, they expect Celgene's share price to reach $107.4737 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. Cantor Fitzgerald analysts commented, "We think Celgene remains a show-me story to investors, which has the stock trading at a discount to peers. We are cautiously optimistic with management changes that execution is improving. We think that the base business remains strong for 2019, and we think filing key late-stage programs over 2019 will help get the stock back on track. The company has many late-stage programs like liso-cel, luspatercept, ozanimod in MS. bb2121 that could launch in late 19/early 2020. Valuation Summary We have a $100 PT on the shares." (1/3/2019)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Celgene is also currently working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla among others, which is encouraging. Meanwhile, the company is focussed on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline to revive its portfolio. Luspatercept looks promising as well with positive data from two late-stage trials. However, shares have underperformed the industry in the year so far. The company’s dependence on Revlimid sales is a concern as well. Celgene suffered a setback when it received a Refusal to File letter from the FDA, regarding the NDA for ozanimod in relapsing multiple sclerosis." (12/31/2018)
  • 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
  • 4. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
  • 5. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)

Has Celgene been receiving favorable news coverage?

News coverage about CELG stock has been trending positive on Thursday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celgene earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the stock's share price in the immediate future.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 62)
  • Dr. S. J. Rupert Vessey, Pres of Research & Early Devel. (Age 53)
  • Mr. David V. Elkins, Exec. VP & CFO
  • Mr. Aijaz Tobaccowalla, Sr. VP and Chief Digital & Information Officer (Age 51)

Who are Celgene's major shareholders?

Celgene's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Factory Mutual Insurance Co. (0.12%), LGT Capital Partners LTD. (0.10%), Gateway Investment Advisers LLC (0.07%), Gofen & Glossberg LLC IL (0.06%), Personal Capital Advisors Corp (0.04%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Cullinan Associates Inc., Highland Capital Management LLC, Patten & Patten Inc. TN, Gibraltar Capital Management Inc., Capital Investment Services of America Inc., Personal Capital Advisors Corp and North Star Investment Management Corp.. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin and Michael D Casey. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., LGT Capital Partners LTD., DNB Asset Management AS, Virtu Financial LLC, Boston Advisors LLC, Centre Asset Management LLC, First Citizens Bank & Trust Co. and Oakbrook Investments LLC. Company insiders that have bought Celgene stock in the last two years include John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $87.00.

How big of a company is Celgene?

Celgene has a market capitalization of $61.69 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

What is Celgene's official website?

The official website for Celgene is

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,923 (Vote Outperform)
Underperform Votes:  682 (Vote Underperform)
Total Votes:  2,605
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by Staff

Featured Article: Front-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel